Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.

Szczegóły
Abstrakt

Tytuł:: Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.
Autorzy:: Gribben JG; Barts Cancer Institute, St. Bartholomew's Hospital, Queen Mary University of London, London, UK.
Źródło:: British journal of haematology [Br J Haematol] 2020 Mar; Vol. 188 (6), pp. 844-851. Date of Electronic Publication: 2019 Dec 19.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Review
Język:: English
Imprint Name(s):: Publication: Oxford : Wiley-Blackwell
Original Publication: Oxford : Blackwell Scientific Publications
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Bridged Bicyclo Compounds, Heterocyclic/*adverse effects
Leukemia, Lymphocytic, Chronic, B-Cell/*complications
Sulfonamides/*adverse effects
Tumor Lysis Syndrome/*etiology
Aged ; Antineoplastic Agents/pharmacology ; Bridged Bicyclo Compounds, Heterocyclic/pharmacology ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Male ; Middle Aged ; Sulfonamides/pharmacology ; Sulfonamides/therapeutic use ; Tumor Lysis Syndrome/drug therapy
References:: J Clin Oncol. 2008 Jun 1;26(16):2767-78. (PMID: 18509186)
N Engl J Med. 2018 Mar 22;378(12):1107-1120. (PMID: 29562156)
N Engl J Med. 2000 Dec 28;343(26):1910-6. (PMID: 11136261)
Blood. 2019 Jun 27;133(26):2765-2775. (PMID: 30862645)
Clin Cancer Res. 2017 Aug 15;23(16):4527-4533. (PMID: 28100580)
Ann Oncol. 2021 Jan;32(1):23-33. (PMID: 33091559)
Lancet Oncol. 2016 Jun;17(6):768-778. (PMID: 27178240)
Lancet Oncol. 2018 Jan;19(1):65-75. (PMID: 29246803)
J Natl Cancer Inst. 1999 May 19;91(10):861-8. (PMID: 10340906)
Br J Haematol. 2010 May;149(4):578-86. (PMID: 20331465)
Br J Haematol. 2015 Jun;169(5):661-71. (PMID: 25876990)
N Engl J Med. 2011 May 12;364(19):1844-54. (PMID: 21561350)
Lancet Oncol. 2017 Feb;18(2):230-240. (PMID: 28089635)
J Clin Oncol. 2019 Feb 1;37(4):269-277. (PMID: 30523712)
Blood. 2018 Apr 12;131(15):1704-1711. (PMID: 29305552)
Grant Information:: International Williams; International AbbVie
Contributed Indexing:: Keywords: case studies; chronic lymphocytic leukaemia; risk management; tumour lysis syndrome; venetoclax
Substance Nomenclature:: 0 (Antineoplastic Agents)
0 (Bridged Bicyclo Compounds, Heterocyclic)
0 (Sulfonamides)
N54AIC43PW (venetoclax)
Entry Date(s):: Date Created: 20191221 Date Completed: 20201113 Latest Revision: 20231113
Update Code:: 20240105
PubMed Central ID:: PMC7154710
DOI:: 10.1111/bjh.16345
PMID:: 31858596
: Czasopismo naukowe

Full Text Finder

The treatment landscape in relapsed/refractory chronic lymphocytic leukaemia (CLL) has rapidly evolved over the past five years, with one such emergent treatment being the BCL2 inhibitor, venetoclax. This oral treatment has demonstrated significant clinical advantages in indicated patients, but rapid tumour debulking can lead to a treatment-related risk of the acute condition known as tumour lysis syndrome (TLS). Here, I present real patient cases to show how I have used the recommended predose monitoring and prophylactic procedures to mitigate the risk of TLS. I also used the ramp-up dose escalation schedule of venetoclax therapy initiation to safely take patients through the treatment, successfully providing them with sustained clinical benefits.
(© 2019 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)

Informacja